News
OPTN
9.14
-0.11%
-0.01
Weekly Report: what happened at OPTN last week (0324-0328)?
Weekly Report · 2d ago
Optinose Reports Revenue Growth Amid Financial Challenges
TipRanks · 5d ago
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More
NASDAQ · 03/26 14:02
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/26 12:10
Form 10-K for the fiscal year ended December 31, 2024
Press release · 03/26 11:51
OptiNose GAAP EPS of -$0.03 beats by $0.76, revenue of $22.42M beats by $1.6M
Seeking Alpha · 03/26 11:26
OptiNose Inc. Q4 Loss Decreases, Beats Estimates
NASDAQ · 03/26 11:13
Press Release: Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
Dow Jones · 03/26 11:00
*Optinose 4Q Rev $22.4M >OPTN
Dow Jones · 03/26 11:00
*Optinose 4Q Loss/Shr 3c >OPTN
Dow Jones · 03/26 11:00
Weekly Report: what happened at OPTN last week (0317-0321)?
Weekly Report · 03/24 09:12
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
NASDAQ · 03/21 16:44
Optinose Cut to Neutral From Overweight by Piper Sandler
Dow Jones · 03/21 15:36
Optinose Price Target Cut to $9.00/Share From $15.00 by Piper Sandler
Dow Jones · 03/21 15:36
OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN
Barchart · 03/21 15:34
Piper Sandler Downgrades OptiNose to Neutral, Lowers Price Target to $9
Benzinga · 03/21 15:26
This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
Benzinga · 03/21 13:18
Further Upside For OptiNose, Inc. (NASDAQ:OPTN) Shares Could Introduce Price Risks After 56% Bounce
Simply Wall St · 03/21 12:21
HC Wainwright & Co. Downgrades OptiNose to Neutral, Lowers Price Target to $9
Benzinga · 03/21 12:14
Optinose Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 03/21 12:12
More
Webull provides a variety of real-time OPTN stock news. You can receive the latest news about Optinose through multiple platforms. This information may help you make smarter investment decisions.
About OPTN
More
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. It has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.